CORMEDIX ($CRMD) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.30 per share, beating estimates of $0.27 by $0.03. The company also reported revenue of $39,080,000, beating estimates of $37,690,703 by $1,389,297.
You can see Quiver Quantitative's $CRMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORMEDIX Insider Trading Activity
CORMEDIX insiders have traded $CRMD stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- ELIZABETH HURLBURT (EVP) sold 140,027 shares for an estimated $1,565,669
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CORMEDIX Hedge Fund Activity
We have seen 83 institutional investors add shares of CORMEDIX stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. removed 1,475,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $11,947,500
- ELLIOTT INVESTMENT MANAGEMENT L.P. added 1,320,109 shares (+85.1%) to their portfolio in Q4 2024, for an estimated $10,692,882
- FIRST TURN MANAGEMENT, LLC added 1,021,421 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,273,510
- VOYA INVESTMENT MANAGEMENT LLC removed 694,291 shares (-97.5%) from their portfolio in Q4 2024, for an estimated $5,623,757
- UBS GROUP AG added 340,352 shares (+861.3%) to their portfolio in Q4 2024, for an estimated $2,756,851
- J. GOLDMAN & CO LP added 314,880 shares (+221.1%) to their portfolio in Q4 2024, for an estimated $2,550,528
- VANGUARD GROUP INC added 309,514 shares (+10.1%) to their portfolio in Q4 2024, for an estimated $2,507,063
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORMEDIX Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/19/2024
To track analyst ratings and price targets for CORMEDIX, check out Quiver Quantitative's $CRMD forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
